Figure 4.

Additional data sets further validated a consistent relationship between treatment effects determined after 3 months and 6 months. Scatter plots overlay the additional data (MAb1 and MAb2) with the model‐evaluated data set 2 (Table 2) for (a) the ΔACR50 readouts at 6 months vs 3 months and (b) the log odds ratios of treated vs control at 6 months vs 3 months. The unity line represents equal efficacies at the 2 time points. The symbols represent different drug classes, and solid symbols represent the data points from the external data set. The symbol size reflects the sample size for each treatment arm. With the additional data set, the scaling factor was reestimated to be 1.01 (95%CI: 0.91, 1.10), very similar to the estimated values shown in Figure 2.